New drugs to fight drug-resistant tuberculosis
Official title: C25-modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis
Funded at Hackensack University Medical Center · NIH-11032609 · Data updated 2026-11-12
This study is working on creating new versions of rifabutin, a medicine for tuberculosis, to help people with tough-to-treat drug-resistant strains of the disease, especially those who also have HIV, so they can have better treatment options.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | November 13, 2024 |
| Project end | October 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $265,650 |
| NIH project number | 1R21AI187674-01 |
| Project ID | NIH-11032609 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multidrug-resistant tuberculosis, especially those who are also living with HIV.
✕Less likely to help
Patients with drug-sensitive tuberculosis or those who do not have tuberculosis may not benefit from this research.
What this research studies
This research focuses on developing new analogs of rifabutin, a medication used to treat tuberculosis, to combat drug-resistant strains of the disease. The approach involves synthesizing modified versions of rifabutin that have shown increased potency against multidrug-resistant tuberculosis (MDR-TB) strains. By improving the effectiveness of these drugs, the research aims to provide better treatment options for patients who cannot be treated with standard therapies. The study will evaluate the pharmacokinetic properties of these new compounds to ensure they are safe and effective for use in patients, particularly those co-infected with HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from drug-resistant tuberculosis, potentially improving cure rates and reducing side effects.
How similar studies have gone: Other research has shown promise in developing new drug analogs for tuberculosis, indicating that this approach could be effective.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Ganapathy, Uday — Hackensack University Medical Center
- Study coordinator: Ganapathy, Uday
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.